Personnel changes are still frequent Huaren Pharmaceutical EXECUTIVE Director, Vice President resignation

Pharmaceutical network on May 15 personnel changes are still frequent, Huaren Pharmaceutical Executive Director, Vice President resignedOn May 13, Huaren Pharmaceuticals, a listed company, announced that Shen Hongze, the chief executive officer, had applied to resign as chief executive of the 6th Board of Directors for personal reasons and would not continue to hold other positions after resigning, while Vice President Li Xiaoli had applied to resign as vice president of the 6th Board of Directors for personal reasons and would not continue to hold other positions after resigningShen Hongze and Li Xiaoli's original terms of office are not yet completedata show that Shen Hongze and Li Xiaoli li are in Huaren Pharmaceuticals for many years, gradually promoted, has served several positionsresume shows that Shen Hongze has served as commercial manager, vice-minister of marketing department and commercial manager, marketing minister, marketing director, deputy general manager of the company, and later as ceo of Huaren PharmaceuticalsLi Xiaoli has served as Assistant Minister of Production, Vice Minister of Production, Minister of Production, Assistant General Manager and Minister of Production, Deputy General Manager of the Company, and later Vice President of Huaren PharmaceuticalsAccording to Huaren Pharmaceutical's 2019 financial report, Shen Hongze's pre-tax compensation was RMB1.5845 million and he held 1,061,660 shares of Huaren PharmaceuticalsLi Xiaoli's pre-tax salary was RMB463,800 and he held 802,530 shares of Huaren PharmaceuticalsFor some time now, huaren pharmaceutical personnel changes can be described as intensiveAccording to Seiber Blue Combs, in 2019 alone, Huaren Pharmaceuticals announced the resignation of the CEO, vice president of the number of four people, in addition to the chairman of the board from Zhou Xijian to Yang YidongJuly 19, 2019, Huaren Pharmaceuticals announced that Chairman Zhou Xijian has applied to resign as a director, chairman and member of the Strategic Committee of the Board of Directors, the Remuneration and Assessment Committee and the Nomination CommitteeZhou Xijian no longer holds other positions after his resignationinformation shows that Zhou Xijian had the chairman of the board of directors of Zhongzhu Group, Tao and Investment Industry Group Chairman and other titles, transferred to Amway, Yuelang and other types of direct marketing industry, by the industry called the king of direct salesOn August 6,, the 14th (Interim) meeting of the 6th Board of Directors of Huaren Pharmaceuticals considered and approved the Motion on the Election of the Chairman of the 6th Board of Directors of the Company, and the Board of Directors elected Yang Yidong as chairman of the 6th Board of DirectorsJuly 31, 2019, Huaren Pharmaceuticals said it had received an application for the resignation of CEO Cai MengjieMr Tsai resigned as CEO for personal reasons and will no longer hold other positions in the company only a few days apart, Huaren Pharmaceuticals issued a further announcement that the board of directors recently received the resignation of the company's chief executive Zhang Chunqiang, ceo Zhang Chunqiang resigned after the resignation of no longer in other positions August 28, 2019, Huaren Pharmaceuticals announced that it had received the resignation application of Xiao Weiwen, Vice President of the Company Shaw Weiwen resigned as Vice President for personal reasons and will no longer hold other positions in mid-December last year, Huaren Pharmaceuticals issued a further announcement that the board of directors recently received the company's vice president Ji Shengbin's written resignation report Ji Shengbin applied to resign as vice president of the company for personal reasons and will no longer hold other positions behind the high-frequency changes in management is the adjustment of the ownership of Huaren Pharmaceuticals Huaren Pharmaceuticals in the 2019 annual report so introduced themselves - state-controlled pharmaceutical health industry group, mainly engaged in non-PVC soft bag large-capacity preparations (basic infusion, therapeutic infusion, periton dialysis liquid) and raw materials, supporting pharmaceutical packaging materials, and other products research and development, production and sales, is The emergency reserve of Shandong Province fixed-point infusion production , products into the country more than 30 provinces and cities, more than 1000 in the non-PVC soft bag market According to Cypress Blue, at present, Huaren Pharmaceuticals has four major business - infusion business, peritoneal dialysis liquid business, fintech business, medical equipment, package business Among them, the infusion business is its largest business, but also its main source of profit state-controlled pharmaceutical and health industry group this positioning is derived from huaren pharmaceutical in 2019 a share transfer July 29, 2019, Huaren Pharmaceuticals issued an evening announcement that the company's former controlling shareholders Guangdong Yongyu Hengfeng Investment and Yongyu Hengfeng Investment Management Agreement transfer of 20% of the company's shares have been transferred the completion of the share transfer, Tianxian Health has a total share voting rights of 26.6% of the listed company, become the controlling shareholder of the company, Xi'an Qujiang New Area Management Committee becomes the actual controller before this change of the real controller, in 2016 Huaren Pharmaceuticals also had a real controller change - the real controller from Huaren Century Group to Yongyu Hengfeng investment, Yongyu Hengfeng management common actual controller Zhou Xijian In addition to the constant adjustment of the controller and management is worthy of attention, Huaren Pharmaceuticals continues to cross the border involving other business is also notable Huaren Pharmaceuticals said that it has been around the company's upstream and downstream industrial chain, seeking new investment opportunities and profit growth points, is committed to growing into a pharmaceutical industry, pharmaceutical business, medical services in one of the pharmaceutical and health industry group , for example, huaren Pharmaceuticals had intended to buy Han last year, but the restructuring was eventually terminated Huaren Pharmaceuticals believes that this transaction will help it create new profit growth points, and combine the existing pharmaceutical and health industry, to create pharmaceutical health and beautiful health two major consumption upgrade scenario time to 2020, under the strict form of the new crown epidemic, Huaren has announced that it will be remodeled medical mask production line and melt spray nonwoven production line project in addition, the fintech trade segment also appears to be Huaren Pharmaceuticals' new business in 2019, and the expression of this segment of the business has not yet appeared in its 2018 annual report The external development environment of enterprises is changing rapidly, and the constant search for new growth points is the inevitable action of many pharmaceutical companies In fact, from the performance of performance, Huaren Pharmaceutical's revenue and net profit is a steady increase in 2019, Huaren Pharmaceuticals achieved operating income of RMB1,462 million, up 5.64% YoY, and net profit attributable to shareholders of listed companies was RMB42,066.2 million, up 8.43% YoY however, as an infusion business-based pharmaceutical companies, the outbreak of the new crown outbreak or make Huaren Pharmaceutical's production and operation has been affected to a certain extent Huaren Pharmaceuticals said in its 2019 annual report, "Infusion products are the main end customer is a hospital, in early 2020, the outbreak of new coronavirus pneumonia outbreak, most hospitals in the country are affected to varying degrees, many hospitals closed some outpatient departments, reduce the inpatient admission, many ordinary In order to reduce the risk of infection, patients cancel or postpone hospital visits, resulting in hospital outpatient spending, hospitalizations during the outbreak decline, during the outbreak of the company's production, logistics and distribution, marketing work by a certain degree of restrictions, production and operation by a certain degree of impact, the company's infusion products have the risk of declining sales." in addition to the impact of the , the large infusion industry, in recent years, but also by the health insurance control fees, limited transmission limit anti-limited auxiliary, outpatient limit and other factors, the total capacity of the entire infusion market has been reduced, industrial concentration is also gradually increasing in addition, , the market competition in large infusion, the cost of rising, profit margin compression and other industry factors superimposed on 4 plus 7 band volume procurement, two-vote system, price reduction, medical insurance control fees and consistency evaluation and other countries a new round of medical reform policy to the industry impact, the development of large infusion drug companies face certain pressure optimistic from the medium to long-term, with the sustained economic growth, the gradual improvement of the health insurance system, the aging of the population, people's awareness of health and the rapid growth of medical rigid expenditure, the pharmaceutical industry will continue to maintain sales revenue continued to grow the impact of unexpected events, changes in the real controller, executive iterations, business expansion and contraction are more or less faced by a pharmaceutical company in the development process, the same is the long-term commitment of enterprises to the value of the industry and the legitimate pursuit of interests.